Angiogenesis Inhibition in Prostate Cancer: Current Uses and Future Promises

被引：28

作者：

Aragon-Ching, Jeanny B. ^{[1
]}

Madan, Ravi A. ^{[2
]}

Dahut, William L. ^{[3
]}

机构：

[1] George Washington Univ, Med Ctr, Dept Med, Div Hematol & Oncol, 2150 Penn Ave Northwest, Washington, DC 20037 USA

[2] NCI, Lab Tumor Immunol & Biol, NIH, Bethesda, MD 20892 USA

[3] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA

来源：

JOURNAL OF ONCOLOGY | 2010年 / 2010卷

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1155/2010/361836

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Angiogenesis has been well recognized as a fundamental part of a multistep process in the evolution of cancer progression, invasion, and metastasis. Strategies for inhibiting angiogenesis have been one of the most robust fields of cancer investigation, focusing on the vascular endothelial growth factor (VEGF) family and its receptors. There are numerous regulatory drug approvals to date for the use of these agents in treating a variety of solid tumors. While therapeutic efficacy has been established, challenges remain with regards to overcoming resistance and assessing response to antiangiogenic therapies. Prostate cancer is the most common noncutaneous malignancy among American men and angiogenesis plays a role in disease progression. The use of antiangiogenesis agents in prostate cancer has been promising and is hereby explored.

引用

页数：7

共 63 条

[1]

[Anonymous], 2009, BEV APPR

[2] Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer [J].

Aragon-Ching, Jeanny B. ;

Jain, Lokesh ;

Gulley, James L. ;

Arlen, Philip M. ;

Wright, John J. ;

Steinberg, Seth M. ;

Draper, David ;

Venitz, Juergen ;

Jones, Elizabeth ;

Chen, Clara C. ;

Figg, William D. ;

Dahut, William L. .

BJU INTERNATIONAL, 2009, 103 (12) :1636-1640

[3] Role of tyrosine kinase inhibitors in cancer therapy [J].

Arora, A ;

Scholar, EM .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) :971-979

[4] Tumorigenesis and the angiogenic switch [J].

Bergers, G ;

Benjamin, LE .

NATURE REVIEWS CANCER, 2003, 3 (06) :401-410

[5] Effects of angiogenesis inhibitors on multistage carcinogenesis in mice [J].

Bergers, G ;

Javaherian, K ;

Lo, KM ;

Folkman, J ;

Hanahan, D .

SCIENCE, 1999, 284 (5415) :808-812

[6] Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

[7] Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting [J].

Borre, M ;

Offersen, BV ;

Nerstrom, B ;

Overgaard, J .

BRITISH JOURNAL OF CANCER, 1998, 78 (07) :940-944

[8] Tumor cell proliferation and survival in patients with prostate cancer followed expectantly [J].

Borre, M ;

Bentzen, SM ;

Nerstrom, B ;

Overgaard, J .

JOURNAL OF UROLOGY, 1998, 159 (05) :1609-1614

[9] Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies [J].

Bostwick, DG ;

Wheeler, TM ;

Blute, M ;

Barrett, DM ;

MacLennan, GT ;

Sebo, TJ ;

Scardino, PT ;

Humphrey, PA ;

Hudson, MA ;

Fradet, Y ;

Miller, GJ ;

Crawford, ED ;

Blumenstein, BA ;

Mahran, HE ;

Miles, BJ .

UROLOGY, 1996, 48 (01) :47-57

[10] Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors [J].

Casanovas, O ;

Hicklin, DJ ;

Bergers, G ;

Hanahan, D .

CANCER CELL, 2005, 8 (04) :299-309

← 1 2 3 4 5 6 7 →